1 Unidad de Tuberculosis, Vall d'Hebrón-Drassanes, Hospital Universitari Vall d'Hebrón.
Ann Am Thorac Soc. 2015 May;12(5):680-8. doi: 10.1513/AnnalsATS.201408-394OC.
The identification of patients with latent tuberculosis infection, who are at higher risk to develop active disease, is an important component of disease control.
We aim to compare the usefulness of the QuantiFERON-TB Gold in-tube assay and the tuberculin skin test to predict the development of active tuberculosis during follow-up, using positive and negative predictive values, positive likelihood ratios, and stratified level of risk.
The study included contacts of tuberculosis cases diagnosed between 2007 and 2009. All contacts included were from the first circle of exposure. Tuberculin skin test and QuantiFERON test were performed and a chest radiograph was obtained during the contact's study.
A total of 1,335 contacts were followed up for 4 years: a smear-positive index case was identified for 937 contacts, of whom 15 developed active tuberculosis and had initially presented with positive tuberculin skin test/QuantiFERON results, a normal chest radiograph, and no symptoms. The positive predictive value was 4% for QuantiFERON and 2% for the tuberculin skin test (when ≥5 mm). The probability of developing active disease was 2.36 times higher with a positive QuantiFERON, and 1.3 times higher with a positive tuberculin skin test. The positive predictive value was 17%, and the positive likelihood ratio was 7.53 for untreated contacts with a positive QuantiFERON. Stratifying according to initial QuantiFERON results showed a 6.36 times higher risk of developing active tuberculosis for patients with a QuantiFERON result greater than or equal to 10 IU/ml. Among bacillus Calmette-Guérin-vaccinated patients, a tuberculin skin test induration greater than or equal to 15 mm correlated better with a positive QuantiFERON.
QuantiFERON results were more accurate than tuberculin skin test results in predicting tuberculosis. Although all contacts with QuantiFERON-positive results are at risk of developing tuberculosis, those with a tuberculin skin test induration greater than or equal to 15 mm and QuantiFERON greater than or equal to 10 IU/ml are at highest risk. This has important implications in the clinical management of tuberculosis contacts.
识别潜伏性结核感染患者(其发生活动性疾病的风险较高)是疾病控制的重要组成部分。
我们旨在通过阳性和阴性预测值、阳性似然比以及分层风险水平,比较结核分枝杆菌干扰素释放试验(QuantiFERON-TB Gold 试剂盒)和结核菌素皮肤试验(TST)预测随访期间发生活动性结核病的作用。
该研究纳入了 2007 年至 2009 年间诊断的结核病病例的接触者。所有纳入的接触者均来自第一级接触者。在接触者研究期间进行 TST 和 QuantiFERON 检测,并进行胸部 X 线检查。
共有 1335 名接触者随访了 4 年:937 名接触者中发现了 1 例涂阳指数病例,其中 15 名接触者最初的 TST/QuantiFERON 结果阳性、胸部 X 线正常且无症状,但发展为活动性结核病。QuantiFERON 的阳性预测值为 4%,TST 为 2%(当硬结直径≥5mm 时)。QuantiFERON 阳性者发生活动性疾病的可能性高 2.36 倍,TST 阳性者高 1.3 倍。对于未治疗的 QuantiFERON 阳性接触者,阳性预测值为 17%,阳性似然比为 7.53。根据初始 QuantiFERON 结果分层显示,QuantiFERON 结果≥10IU/ml 的患者发生活动性结核病的风险高 6.36 倍。在卡介苗接种者中,硬结直径≥15mm 的 TST 与 QuantiFERON 阳性的相关性更好。
QuantiFERON 结果比 TST 结果更能准确预测结核病。虽然所有 QuantiFERON 阳性结果的接触者都有发生结核病的风险,但硬结直径≥15mm 且 QuantiFERON≥10IU/ml 的接触者发生结核病的风险最高。这对结核病接触者的临床管理具有重要意义。